Drug Trial Radar · NCT06786234
A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 18, 2025
Primary completion
Jun 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Step Pharma, SASIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are: * Does STP938 control platelet counts * Does STP938 control platelet counts without inducing unwanted side effects Participants will: * Take STP938 every day for up to 12 months. * Visit the clinic once every week for the first month, then every 2 weeks for checkups and tests. * Complete a questionnaire about symptoms once a month.
Conditions
- Essential Thrombocythaemia
Interventions
STP938Drug
At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical EfficacyTime frame: Through study completion, an average of 12 months
- Safety and TolerabilityTime frame: Through study completion, an average of 12 months
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
CHU Brest
Brest, France · Recruiting
Institut Paoli-Calmettes
Marseille, France · Recruiting
CHU Nantes
Nantes, France · Recruiting
CHU Nice
Nice, France · Recruiting
CHU Nîmes
Nîmes, France · Recruiting
Hôpital Saint-Louis
Paris, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Hôpital de la Milétrie, CHU
Poitiers, New Aquitaine, France · Not yet recruiting
University Hospital of Wales
Cardiff, United Kingdom · Recruiting
Imperial College London / Hammersmith Hospital
London, United Kingdom · Recruiting
Sarah Cannon Research Institute
London, United Kingdom · Recruiting
Cancer and Haematology Centre, Churchill Hospital
Oxford, United Kingdom · Recruiting
University of Southampton Hospital
Southampton, United Kingdom · Recruiting
Royal Hallamshire Hospital
Sheffield, South Yorkshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.